Rezafungin Prophylaxis in Liver Transplant

This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.

Inclusion Criteria: * Liver transplant recipient * 18 years of age or older * ≥1 risk factor(s) for IFI: living donor transplant, retransplantation, complicated operations (based on duration of transplant and number of blood products required in the peri-transplant period), choledochojejunostomy anastomosis, or peri-operative Candida colonization, recent Candida infection, renal replacement therapy post-transplant, and reoperation within the first 90 days of transplant. Exclusion Criteria: * Participants who are perceived not to survive past 7 days after transplant * Participants who elect not to participate in the prospective trial * Participants who had active candidiasis at the time of transplant * Participants with a history of allergy to an echinocandin * Participants who are pregnant.